BR112020026580A2 - Compostos, composição farmacêutica e métodos para tratar um paciente - Google Patents
Compostos, composição farmacêutica e métodos para tratar um paciente Download PDFInfo
- Publication number
- BR112020026580A2 BR112020026580A2 BR112020026580-2A BR112020026580A BR112020026580A2 BR 112020026580 A2 BR112020026580 A2 BR 112020026580A2 BR 112020026580 A BR112020026580 A BR 112020026580A BR 112020026580 A2 BR112020026580 A2 BR 112020026580A2
- Authority
- BR
- Brazil
- Prior art keywords
- optionally substituted
- group
- alkyl
- hydrogen
- heterocyclic
- Prior art date
Links
- JJWQWBSHXYDCIR-VWRAKTAISA-N CC(C)(C[C@@H]1C(CC2)N(CC(c(cc3C)c(C)[n]3-c(cc3)ccc3C#N)=O)C2C1)O Chemical compound CC(C)(C[C@@H]1C(CC2)N(CC(c(cc3C)c(C)[n]3-c(cc3)ccc3C#N)=O)C2C1)O JJWQWBSHXYDCIR-VWRAKTAISA-N 0.000 description 1
- VKSBMNUHAZFWQZ-PVVBHEMZSA-N C[C@@H](C1CCC1)c1cc(C(CN(C(CC2)C3)C2[C@H]3O)=O)c(C)[n]1-c(cc1)ccc1C#N Chemical compound C[C@@H](C1CCC1)c1cc(C(CN(C(CC2)C3)C2[C@H]3O)=O)c(C)[n]1-c(cc1)ccc1C#N VKSBMNUHAZFWQZ-PVVBHEMZSA-N 0.000 description 1
- OLTYWSNXDQBLPD-LROQTYINSA-N C[C@@]1(CC(C2)N(CC(c(cc3C)c(C)[n]3-c(cc3)ccc3C#N)=O)[C@H]2C1)O Chemical compound C[C@@]1(CC(C2)N(CC(c(cc3C)c(C)[n]3-c(cc3)ccc3C#N)=O)[C@H]2C1)O OLTYWSNXDQBLPD-LROQTYINSA-N 0.000 description 1
- VKSBMNUHAZFWQZ-GJUDNMQLSA-N C[C@H](C1CCC1)c1cc(C(CN(C(CC2)C3)C2[C@H]3O)=O)c(C)[n]1-c(cc1)ccc1C#N Chemical compound C[C@H](C1CCC1)c1cc(C(CN(C(CC2)C3)C2[C@H]3O)=O)c(C)[n]1-c(cc1)ccc1C#N VKSBMNUHAZFWQZ-GJUDNMQLSA-N 0.000 description 1
- OODUHKBKQNPCIE-ZNIKRAEXSA-N Cc([n](c(-c1cnc(C)[s]1)c1)-c(cc2)ccc2C#N)c1C(CN(C(CC1)C2)C1[C@H]2O)=O Chemical compound Cc([n](c(-c1cnc(C)[s]1)c1)-c(cc2)ccc2C#N)c1C(CN(C(CC1)C2)C1[C@H]2O)=O OODUHKBKQNPCIE-ZNIKRAEXSA-N 0.000 description 1
- FMBTVPJXAJGBGP-RXNSBXKKSA-N Cc([n](c(/C=C/CN(C(c1c2cccc1)=O)C2=O)c1)-c(cc2)ccc2C#N)c1C(CN(C(CC1)C2)C1[C@H]2O)=O Chemical compound Cc([n](c(/C=C/CN(C(c1c2cccc1)=O)C2=O)c1)-c(cc2)ccc2C#N)c1C(CN(C(CC1)C2)C1[C@H]2O)=O FMBTVPJXAJGBGP-RXNSBXKKSA-N 0.000 description 1
- FVFKNYGFGZDCPE-MVOSBBFYSA-N Cc([n](c(/C=C/CN)c1)-c(cc2)ccc2C#N)c1C(CN(C(CC1)C2)C1[C@H]2O)=O Chemical compound Cc([n](c(/C=C/CN)c1)-c(cc2)ccc2C#N)c1C(CN(C(CC1)C2)C1[C@H]2O)=O FVFKNYGFGZDCPE-MVOSBBFYSA-N 0.000 description 1
- ACDYXBCCRUMFPS-QAWDVHMMSA-N Cc([n](c(CC1(C2)CC2C1)c1)-c(cc2)ccc2C#N)c1C(CN(C(CC1)C2)C1[C@H]2O)=O Chemical compound Cc([n](c(CC1(C2)CC2C1)c1)-c(cc2)ccc2C#N)c1C(CN(C(CC1)C2)C1[C@H]2O)=O ACDYXBCCRUMFPS-QAWDVHMMSA-N 0.000 description 1
- GEMGFVQCBVLHMD-HXJXPZHGSA-N Cc([n](c(CC1(CCC1)Cl)c1)-c(cc2)ccc2C#N)c1C(CN(C(CC1)C2)C1[C@H]2O)=O Chemical compound Cc([n](c(CC1(CCC1)Cl)c1)-c(cc2)ccc2C#N)c1C(CN(C(CC1)C2)C1[C@H]2O)=O GEMGFVQCBVLHMD-HXJXPZHGSA-N 0.000 description 1
- IXUBHGGQAQBXNO-UDJZJCJKSA-N Cc([n](c(CCCOC(F)(F)F)c1)-c(cc2)ccc2C#N)c1C(CN(C(CC1)C2)C1[C@H]2O)=O Chemical compound Cc([n](c(CCCOC(F)(F)F)c1)-c(cc2)ccc2C#N)c1C(CN(C(CC1)C2)C1[C@H]2O)=O IXUBHGGQAQBXNO-UDJZJCJKSA-N 0.000 description 1
- VVIOHUFPRYYZDZ-ADKAHSJRSA-N Cc1c(C(CN(C(CC2)C3)C2[C@H]3C(F)(F)F)=O)c(F)c(C)[n]1-c(cc1)ccc1C#N Chemical compound Cc1c(C(CN(C(CC2)C3)C2[C@H]3C(F)(F)F)=O)c(F)c(C)[n]1-c(cc1)ccc1C#N VVIOHUFPRYYZDZ-ADKAHSJRSA-N 0.000 description 1
- IHLWUFKOECDBJB-UHFFFAOYSA-N Cc1c(C(CN2C3C(C(F)(F)F)=CC2CC3)=O)c(F)c(C)[n]1-c(cc1)ccc1C#N Chemical compound Cc1c(C(CN2C3C(C(F)(F)F)=CC2CC3)=O)c(F)c(C)[n]1-c(cc1)ccc1C#N IHLWUFKOECDBJB-UHFFFAOYSA-N 0.000 description 1
- AMUXQRPFQSXBNR-UHFFFAOYSA-N Cc1c(C(CN2C3CCC2CC3)=O)c(F)c(C)[n]1-c(cc1)ccc1C#N Chemical compound Cc1c(C(CN2C3CCC2CC3)=O)c(F)c(C)[n]1-c(cc1)ccc1C#N AMUXQRPFQSXBNR-UHFFFAOYSA-N 0.000 description 1
- BMTONVKSFOUUTN-SYYJFZTOSA-N Cc1cc(C(CN(C(CC2)C3)C2[C@H]3C(F)(F)F)=O)c(C)[n]1-c(cc1)ccc1C#N Chemical compound Cc1cc(C(CN(C(CC2)C3)C2[C@H]3C(F)(F)F)=O)c(C)[n]1-c(cc1)ccc1C#N BMTONVKSFOUUTN-SYYJFZTOSA-N 0.000 description 1
- QVPKNTKBAJMSKZ-XTXLOEGASA-N Cc1cc(C(CN(C(CC2)C3)C2[C@H]3OC(F)(F)F)=O)c(C)[n]1-c(cc1)ccc1C#N Chemical compound Cc1cc(C(CN(C(CC2)C3)C2[C@H]3OC(F)(F)F)=O)c(C)[n]1-c(cc1)ccc1C#N QVPKNTKBAJMSKZ-XTXLOEGASA-N 0.000 description 1
- HBIPPZSXFLNFIV-ZNIKRAEXSA-N Cc1cc(C(CN(C(CC2)C3)C2[C@H]3OC)=O)c(C)[n]1-c(cc1)ccc1C#N Chemical compound Cc1cc(C(CN(C(CC2)C3)C2[C@H]3OC)=O)c(C)[n]1-c(cc1)ccc1C#N HBIPPZSXFLNFIV-ZNIKRAEXSA-N 0.000 description 1
- NECNLMQUOLCSTD-BPYOIECJSA-N Cc1cc(C(CN([C@H](CC2)C3)C2[C@H]3O)=O)c(C)[n]1-c(cc1)ccc1C#N Chemical compound Cc1cc(C(CN([C@H](CC2)C3)C2[C@H]3O)=O)c(C)[n]1-c(cc1)ccc1C#N NECNLMQUOLCSTD-BPYOIECJSA-N 0.000 description 1
- QDSILNCNPSMOHI-DRQLIRHJSA-N Cc1cc(C(CN2C(C3)(C4)C3CC2C[C@@H]4O)=O)c(C)[n]1-c(cc1)ccc1C#N Chemical compound Cc1cc(C(CN2C(C3)(C4)C3CC2C[C@@H]4O)=O)c(C)[n]1-c(cc1)ccc1C#N QDSILNCNPSMOHI-DRQLIRHJSA-N 0.000 description 1
- QDSILNCNPSMOHI-VAHJRBIFSA-N Cc1cc(C(CN2C(C3)(C4)C3CC2C[C@H]4O)=O)c(C)[n]1-c(cc1)ccc1C#N Chemical compound Cc1cc(C(CN2C(C3)(C4)C3CC2C[C@H]4O)=O)c(C)[n]1-c(cc1)ccc1C#N QDSILNCNPSMOHI-VAHJRBIFSA-N 0.000 description 1
- OYRANNNUFJKOTD-UHFFFAOYSA-N Cc1cc(C(CN2C3CCCC2CC3)=O)c(C)[n]1-c(cc1)ccc1C#N Chemical compound Cc1cc(C(CN2C3CCCC2CC3)=O)c(C)[n]1-c(cc1)ccc1C#N OYRANNNUFJKOTD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR122023023216-0A BR122023023216A2 (pt) | 2018-06-27 | 2019-06-27 | Compostos, composição farmacêutica e uso de uma quantidade eficaz de um composto |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862690563P | 2018-06-27 | 2018-06-27 | |
| US201862690565P | 2018-06-27 | 2018-06-27 | |
| US62/690,565 | 2018-06-27 | ||
| US62/690,563 | 2018-06-27 | ||
| PCT/US2019/039600 WO2020006296A1 (en) | 2018-06-27 | 2019-06-27 | Proteasome activity enhancing compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020026580A2 true BR112020026580A2 (pt) | 2021-03-23 |
Family
ID=67439356
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020026580-2A BR112020026580A2 (pt) | 2018-06-27 | 2019-06-27 | Compostos, composição farmacêutica e métodos para tratar um paciente |
| BR122023023216-0A BR122023023216A2 (pt) | 2018-06-27 | 2019-06-27 | Compostos, composição farmacêutica e uso de uma quantidade eficaz de um composto |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR122023023216-0A BR122023023216A2 (pt) | 2018-06-27 | 2019-06-27 | Compostos, composição farmacêutica e uso de uma quantidade eficaz de um composto |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11560385B2 (https=) |
| EP (1) | EP3814338A1 (https=) |
| JP (2) | JP7561632B2 (https=) |
| KR (1) | KR20210024588A (https=) |
| CN (1) | CN112585132B (https=) |
| AU (1) | AU2019295765B2 (https=) |
| BR (2) | BR112020026580A2 (https=) |
| CA (1) | CA3103954A1 (https=) |
| CL (1) | CL2020003380A1 (https=) |
| CR (1) | CR20200652A (https=) |
| IL (1) | IL279698A (https=) |
| MA (1) | MA53014A (https=) |
| MX (1) | MX2020014082A (https=) |
| PE (1) | PE20211804A1 (https=) |
| PH (1) | PH12020552261A1 (https=) |
| SG (1) | SG11202013026WA (https=) |
| WO (1) | WO2020006296A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112654621B (zh) | 2018-06-27 | 2024-05-14 | 百时美施贵宝公司 | 可作为t细胞活化剂的经取代萘啶酮化合物 |
| JP7640458B2 (ja) | 2018-10-05 | 2025-03-05 | アンナプルナ バイオ インコーポレイテッド | Ａｐｊ受容体活性に関連する状態を処置するための化合物および組成物 |
| CN111423353B (zh) * | 2020-04-29 | 2022-03-22 | 湖北省生物农药工程研究中心 | 多取代n-芳基吡咯类化合物及其制备方法 |
| CN112142642B (zh) * | 2020-10-15 | 2022-03-04 | 华侨大学 | 一种1,2,3-三取代-5-三氟甲基吡咯衍生物的制备方法 |
| WO2023107597A2 (en) * | 2021-12-08 | 2023-06-15 | Kineta, Inc. | Bicyclic heteroaromatic amide compounds and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1142508A (en) | 1966-04-27 | 1969-02-12 | Whitefin Holding Sa | Pyrrole derivatives |
| GB1154744A (en) | 1966-05-17 | 1969-06-11 | Whitefin Holding Sa | Disubstituted Aminoethanols |
| AP9801302A0 (en) | 1997-07-23 | 2000-01-23 | Pfizer | Indole compounds as anti-inflammatory/analgesic agents.. |
| CZ20002669A3 (cs) | 1998-01-23 | 2001-11-14 | National Jewish Medical And Research Center | Pouľití proteinů tepelného ąoku nebo molekuly nukleové kyseliny, která jej kóduje, přípravek tyto látky obsahující, způsob výběru léčby přecitlivělosti nebo nedostatečnosti průchodu dýchacích cest |
| US7842470B2 (en) | 2001-10-09 | 2010-11-30 | Oregon Health & Science University | Method for pharmacoperones correction of GnRHR mutant protein misfolding |
| US20060148767A1 (en) | 2001-12-06 | 2006-07-06 | George Cioca | Use of acyl salicylates as heat shock inducers |
| EP1682504B1 (en) | 2003-11-12 | 2012-12-26 | Amicus Therapeutics Inc. | Hydroxy piperidine derivatives to treat gaucher disease |
| EP2932982B1 (en) | 2005-05-17 | 2018-10-03 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
| CN101541172A (zh) | 2005-06-08 | 2009-09-23 | 阿米库斯治疗学公司 | 溶酶体酶编码基因突变相关的cns紊乱的治疗 |
| US20070207992A1 (en) | 2006-02-21 | 2007-09-06 | Board Of Trustees Of Michigan State University | Geldanamycin derivatives and method of use thereof |
| WO2007131034A1 (en) | 2006-05-03 | 2007-11-15 | The Regents Of The University Of Michigan | Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70 |
| ES2573498T3 (es) | 2006-05-16 | 2016-06-08 | Amicus Therapeutics, Inc. | Opciones de tratamiento para la enfermedad de Fabry |
| PT1860101E (pt) | 2006-05-24 | 2011-07-12 | Amicus Therapeutics Inc | Sal de tartrato da isofagomina e métodos de uso |
| JP5303458B2 (ja) | 2006-06-23 | 2013-10-02 | アミークス セラピューティックス インコーポレイテッド | β−グルコセレブロシダーゼの活性増強による神経学的疾患の治療方法 |
| US20080119457A1 (en) | 2006-08-24 | 2008-05-22 | Serenex, Inc. | Benzene, Pyridine, and Pyridazine Derivatives |
| WO2009118292A1 (en) | 2008-03-24 | 2009-10-01 | Novartis Ag | Arylsulfonamide-based matrix metalloprotease inhibitors |
| MX336731B (es) * | 2010-01-28 | 2016-01-28 | Harvard College | Composiciones y metodos para potenciar la actividad de proteasoma. |
| DK2707101T3 (da) * | 2011-05-12 | 2019-05-13 | Proteostasis Therapeutics Inc | Proteostaseregulatorer |
| US9849135B2 (en) * | 2013-01-25 | 2017-12-26 | President And Fellows Of Harvard College | USP14 inhibitors for treating or preventing viral infections |
| AU2014282886A1 (en) | 2013-06-17 | 2015-12-17 | Lupin Limited | Pyrrole derivatives as alpha 7 nAChR modulators |
| FR3008977A1 (fr) | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2015073528A1 (en) * | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
-
2019
- 2019-06-27 BR BR112020026580-2A patent/BR112020026580A2/pt unknown
- 2019-06-27 BR BR122023023216-0A patent/BR122023023216A2/pt unknown
- 2019-06-27 WO PCT/US2019/039600 patent/WO2020006296A1/en not_active Ceased
- 2019-06-27 KR KR1020217002233A patent/KR20210024588A/ko not_active Ceased
- 2019-06-27 AU AU2019295765A patent/AU2019295765B2/en not_active Ceased
- 2019-06-27 MX MX2020014082A patent/MX2020014082A/es unknown
- 2019-06-27 CA CA3103954A patent/CA3103954A1/en active Pending
- 2019-06-27 MA MA053014A patent/MA53014A/fr unknown
- 2019-06-27 SG SG11202013026WA patent/SG11202013026WA/en unknown
- 2019-06-27 CR CR20200652A patent/CR20200652A/es unknown
- 2019-06-27 JP JP2020573524A patent/JP7561632B2/ja active Active
- 2019-06-27 PE PE2020002159A patent/PE20211804A1/es unknown
- 2019-06-27 EP EP19744945.7A patent/EP3814338A1/en not_active Withdrawn
- 2019-06-27 CN CN201980055152.2A patent/CN112585132B/zh active Active
-
2020
- 2020-12-23 PH PH12020552261A patent/PH12020552261A1/en unknown
- 2020-12-23 US US17/133,372 patent/US11560385B2/en active Active
- 2020-12-23 IL IL279698A patent/IL279698A/en unknown
- 2020-12-23 CL CL2020003380A patent/CL2020003380A1/es unknown
-
2022
- 2022-11-18 US US18/057,020 patent/US12319698B2/en active Active
-
2024
- 2024-06-12 JP JP2024094936A patent/JP2024138260A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20230183256A1 (en) | 2023-06-15 |
| WO2020006296A1 (en) | 2020-01-02 |
| US20210115057A1 (en) | 2021-04-22 |
| US12319698B2 (en) | 2025-06-03 |
| EP3814338A1 (en) | 2021-05-05 |
| SG11202013026WA (en) | 2021-01-28 |
| KR20210024588A (ko) | 2021-03-05 |
| PE20211804A1 (es) | 2021-09-14 |
| JP7561632B2 (ja) | 2024-10-04 |
| MA53014A (fr) | 2021-05-05 |
| BR122023023216A2 (pt) | 2024-02-20 |
| PH12020552261A1 (en) | 2021-08-02 |
| CN112585132A (zh) | 2021-03-30 |
| IL279698A (en) | 2021-03-01 |
| JP2021529792A (ja) | 2021-11-04 |
| US11560385B2 (en) | 2023-01-24 |
| CL2020003380A1 (es) | 2021-05-14 |
| CN112585132B (zh) | 2025-02-28 |
| CA3103954A1 (en) | 2020-01-02 |
| MX2020014082A (es) | 2021-04-13 |
| AU2019295765B2 (en) | 2024-08-29 |
| JP2024138260A (ja) | 2024-10-08 |
| AU2019295765A1 (en) | 2021-01-21 |
| CR20200652A (es) | 2021-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12319698B2 (en) | Proteasome activity enhancing compounds | |
| KR102757890B1 (ko) | 화합물, 조성물 및 방법 | |
| TWI457340B (zh) | 環狀苯胺基-吡啶并三類 | |
| AU2017281907B2 (en) | Small molecule modulators of pantothenate kinases | |
| ES2724531T3 (es) | Reguladores de proteostasis | |
| BRPI0713187A2 (pt) | método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica | |
| AU2016266190A1 (en) | Urea derivative or pharmacologically acceptable salt thereof | |
| CN106715440A (zh) | 咪唑并异吲哚类衍生物、其制备方法及其在医药上的应用 | |
| CN109111385B (zh) | 5-ht2a受体抑制剂及其制备方法和应用 | |
| BR112020017644A2 (pt) | Piperidinil-3-(arilóxi)propanamidas e propanoatos | |
| WO2015073528A1 (en) | Proteasome activity enhancing compounds | |
| EP3194403A1 (en) | Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists | |
| IL259818A (en) | Isoindole compounds | |
| AU2005206308A1 (en) | Substituted N-cyclohexyl imidazolinones having an MCH-modulatory effect | |
| TW202231272A (zh) | 新穎化合物 | |
| US12054486B2 (en) | Pyridine derivatives and their use as sodium channel activators | |
| PT2370442E (pt) | 3-aminociclopentanocarboxamidas como moduladores de receptor de quimiocina | |
| EP4433471A1 (en) | N-(2h-indazol-5-yl)pyrazine-2-carboxamide derivatives and similar compounds as htt modulators for the treatment of huntington's disease | |
| ES2892175T3 (es) | Moduladores de los receptores NMDA, composiciones que los incluyen y uso de dichos compuestos en el tratamiento de enfermedades que implican al sistema nervioso central | |
| HK40050827A (en) | Proteasome activity enhancing compounds | |
| HK40050827B (zh) | 蛋白酶体活性增强化合物 | |
| HK40116639A (zh) | 用於治疗弗里德希共济失调的化合物和方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122023023216-0 PROTOCOLO 870230098017 EM 06/11/2023 17:51. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: ARQUIVADO O PEDIDO DE PATENTE, NOS TERMOS DO ARTIGO 86, DA LPI, E ARTIGO 14 DA PORTARIA 52/2023, REFERENTE AO NAO RECOLHIMENTO DA 7A RETRIBUICAO ANUAL.PARA FINS DE RESTAURACAO CONFORME ARTIGO 87, DA LPI 9.279, E ARTIGO 15, DA PORTARIA 52/2023, O DEPOSITANTE DEVERA, NO PRAZO DE 3 (TRES) MESES, PROCEDER COM:- PAGAMENTO DA GRU SERVICO 208, REFERENTE A TAXA DE RESTAURACAO DO PEDIDO.- PAGAMENTO DE 1 (UMA) GRU, SERVICO 221, REFERENTE A ANUIDADE EM QUESTAO, NO VALOR EXTRAORDINARIO, CONFORME TABELA VIGENTE, SEGUNDO O ART. 84O 2O DA LEI NO 9.279/96. CASO NAO HAJA PAGAMENTO CONJUNTO, DENTRO DO PRAZO LEGAL, DAS RETRIBUICOES SUPRACITADAS, SERA MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, ATRAVES DO DE |